402. Gait Function in a Canine Model of X-Linked Myotubular Myopathy After Systemic Delivery of AAV8-MTM1

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)35415-6
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

36. AAV-MTM1 Prolongs Survival and Rescues Severe Muscle Weakness in Mouse and Canine Models of X-Linked Myotubular Myopathy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

a Novel Intronic Mutation in MTM1 Detected by RNA Analysis in a Case of X-Linked Myotubular Myopathy

Neurology: Genetics
NeurologyGenetics
2017English

498. Prolonged Benefit From Systemic rAAV8 in a Canine Model of Myotubular Myopathy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2016English

X-Linked Myotubular Myopathy-Abnormal Genitalia Syndrome

2020English

606. Restricting MTM1 Transgene Expression to Skeletal Muscle in AAV-Mediated Gene Therapy for Myotubular Myopathy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2013English

Endoscopic Third Ventriculostomy With Choroid Plexus Coagulation for Treatment of Hydrocephalus in X-Linked Myotubular Myopathy: A Novel Approach

Cureus
2018English

Mutation Identification in a Canine Model of X-Linked Ectodermal Dysplasia

Mammalian Genome
Genetics
2005English

Preclinical Safety Evaluation of a Recombinant AAV8 Vector for X-Linked Retinoschisis After Intravitreal Administration in Rabbits

Human gene therapy. Clinical development
Genetics
2014English

Ocular and Systemic Safety of a Recombinant AAV8 Vector for X-Linked Retinoschisis Gene Therapy: GLP Studies in Rabbits and Rs1-Ko Mice

Molecular Therapy - Methods and Clinical Development
Molecular MedicineGeneticsMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy